Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia

ConditionSarcopenia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-95
SponsorThe Third Affiliated hospital of Zhejiang Chinese Medical University

About this trial

Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia.

Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. Subjects will be randomly assigned in a 1:1 ratio to either EA combined with rehabilitation training group or rehabilitation training group through a central computerized randomization system. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial.

Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

60 years ≤ age ≤ 95 years, male or female;

Patients are able to walk and communicate independently, and can complete required rehabilitation training;

Patients meet the diagnostic criteria proposed by the Asian Working Group for Sarcopenia(AWGS);

Patients volunteer to participate in this study and sign the informed consent.

Disqualifiers

Patients with serious primary diseases of heart, brain, liver, kidney and hematopoietic system;

Patients with severe mental illness, cognitive impairment, and disorientation;

Patients have trauma and unsuitable for sports;

Patients with electronic devices or metal objects implanted in the body;

Trial design

Design model

Parallel

Treatments tested in this trial

  • electroacupuncture

    Device

    Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.

  • Rehabilitation Training

    Behavioral

    The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia. 1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load. 2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: electroacupuncture and rehabilitation trainingExperimental treatment 2 interventions
Group B: rehabilitation training onlyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

6min walk test

The 6-min walking test setup is a straight line of 20 meters on a flat floor, and a chair is placed at each end as a sign. The subjects walk back and forth between them. The pace of walking is determined according to their own physical fitness, and they walk as fast as possible. In this way, the maximum walking distance that an individual can reach within 6 minutes will be texted

Time frame
12 weeks
2

time to get up and go(TGUG)

The TGUG test measures the time it takes for an individual to get up from a chair, complete a short 3 meters round-trip walk, and finally sit back in the chair.

Time frame
12 weeks
3

short physical performance battery (SPPB)

SPPB is a comprehensive test instrument that includes a walking speed test, a sit-to-stand test, and a balance test. The Walking Speed Test measures the time to pass a distance of 4 meters at daily walking speed. Sit-to-stand test is to calculate the time to complete 5 consecutive sets of getting up-sit down. The balance test includes 3 parts: 10 seconds for standing on the left and right side of both feet; standing on half front and half rear feet and standing on front and rear feet

Time frame
12 weeks

Secondary outcomes

1

lower extremity skeletal muscle mass

The skeletal muscle mass of the lower limbs can be detected separately by applying the BCA body composition analyzer produced by Tsinghua Tongfang

Time frame
12 weeks
2

appendicular skeletal muscle mass(ASMM)

The BCA body composition analyzer produced by Tsinghua Tongfang can be used to directly test the skeletal muscle mass of the extremities.

Time frame
12 weeks
3

calf circumference

Measured by applying a measuring tape horizontally around the circumference of the thickest part of the calf

Time frame
12 weeks
4

knee flexion and extension strength

The TB-ISO multi-joint isometric strength testing system (made in Italy) was applied to test the peak moment/peak moment body weight ratio, average power, and total work for the isometric exercise of knee flexion and knee extension, respectively.

Time frame
12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.